Skip to content
619.574.0820

Archive for January 2018

ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC

HOUSTON, January 26, 2018—ZZ Biotech today announced that preliminary results of RHAPSODY, the company’s Phase 2 clinical trial in acute ischemic stroke patients, were presented at the 2018 International Stroke Conference in Los Angeles. The placebo-controlled dose-escalation trial was designed to establish a maximally tolerated dose (MTD) of 3K3A-APC in patients with acute ischemic stroke…

Read More